Pfizer (PFE) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is PFE's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Dividend stocks are being forgotten by investors right now. Pfizer has a diversified portfolio with nice growth potential.…

Novo Nordisk A/S maintains a leading position in the high-growth obesity and diabetes treatment markets. Pfizer offers a highly diversified product portfolio and significant free cash flow generation.…

Pfizer offers one of the highest yields in healthcare. AbbVie is a Dividend King with solid growth prospects.…

Investors are downbeat on Pfizer, at least in part due to concerns about innovation and patent expirations. The company continues to invest in new drugs, but innovation can't be scheduled.…

Pfizer's stock is rallying this year, yet investors who bought near the COVID peak are still underwater, even with every dividend reinvested. A looming 2027 patent test could decide whether that stake ever recovers.…

PFE shares fell despite the company beating Q3 estimates and raising guidance. Explore its growth drivers, pipeline potential, patent risks & attractive valuation.…

A huge yield looks like a bargain until the payout gets cut. Six dividend stocks just hit record yields against their own history, and only some of them can afford what they pay shareholders.…

Pfizer partners with Blackstone, securing up to $1.5bn in funding for berobenatide, a potential first-in-class monthly GLP-1 agonist for obesity. PFE faces stagnant revenues, heavy debt, and looming patent expiries on ke…

PFE gets up to $1.5 billion from Blackstone to fund berobenatide's development through 2028, retaining full control of the obesity program.…

Pfizer just convinced Wall Street's biggest private investor to shoulder its obesity bet, yet the payoff for shareholders may not come from the drug at all. The real story sits in who keeps the upside and what arrives fi…

Blackstone Life Sciences agrees to pay $1.5 billion in development costs for Pfizer's berobenatide through 2028 in exchange for milestone-based payments.…

The investment is set to cover development costs for berobenatide, an investigational drug being studied for chronic weight management and obesity-related conditions.…

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development…

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Blackstone Life Sciences (“Blackstone”) today announced a strategic co-funding agreement under which funds managed by Blackstone will pay up to a …

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Jefferies Londo…

Pfizer's recently launched and acquired products have been generating impressive growth. The stock is up big this year, but its valuation remains modest based on analyst expectations.…

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.…

Pfizer acquired a promising GLP-1 drug last year through its purchase of Metsera. It plans to eventually launch both weekly and monthly versions of the treatment.…

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2026 and raised its full-year 2026 guidance(2) for both Revenues and Adjusted(3) diluted EPS. EXECUTIVE COMMENTARY Dr…

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has unanimously appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026. …

SAN FRANCISCO--(BUSINESS WIRE)--Edison Scientific announces agreement with Pfizer to accelerate research and development.…

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple mye…

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) to the treat…

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872…

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio a…

PARIS--(BUSINESS WIRE)-- #Biotech--Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, today announced it has entered into a …
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 2. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

